CSF3R and atypical chronic myeloid leukemia, BCR-ABL1 negative: After a few case reports on the successful use of ruxolitinib in patients with CSF3R mutations, a phase II study including 23 patients with aCML, six of whom carried an activating mutation of CSF3R reported an overall response rate of only 8.7% (18).